RxDoctor Payments DataLook up a doctor →

Carl Rose, PA

Medical · Westmoreland, TNNPI 1740326495

Payments from drug & device makers

$9,705in general payments, 2019–2025

Across 573 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$582
  • GSK$492
  • Lilly USA, LLC$492
  • Otsuka America Pharmaceutical, Inc.$483
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$9,62599%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,705 in reported general payments places this provider in the 95th percentile of 480 medical providers in Tennessee.

See all medical providers in Tennessee

Medicare billing

Part B allowed, 2024
$63,360
Medicare patients
214
Services billed
3,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$178,490
JardianceEmpagliflozin113$108,412
FarxigaDapagliflozin Propanediol97$101,984
RexultiBrexpiprazole59$89,845
QuliptaAtogepant61$80,599
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$80,360
EliquisApixaban75$73,950
MounjaroTirzepatide64$71,035
RybelsusSemaglutide52$66,721
Tresiba Flextouch U-200Insulin Degludec72$55,177
LinzessLinaclotide60$53,733
JanuviaSitagliptin Phosphate46$43,828
UbrelvyUbrogepant23$37,207
XareltoRivaroxaban36$33,905
VraylarCariprazine Hcl19$29,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,427$245,211189 claims
AbbVieQulipta, Linzess, Ubrelvy, Vraylar, Creon$1,452$232,322201 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$245$139,570153 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$582$132,620161 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$492$106,077148 claims
Lilly USA, LLCMounjaro, Trulicity$492$99,87088 claims
Otsuka America Pharmaceutical, Inc.Rexulti$483$89,84559 claims
PfizerEliquis, Nurtec Odt$452$87,85290 claims
MerckJanuvia, Belsomra$46$51,29262 claims
Johnson & JohnsonXarelto$37$33,90536 claims
NovartisEntresto$62$14,15812 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$259$11,92421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 480 medical providers in Tennessee.

Other medical in Westmoreland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →